Introduction:
Pharmacistsalready have an essential role in screening for Diabetes mellites and Cardiovascular risk and their involvement has beneficial effects in patient education and disease management [1] [2]. Pharmacist-led health screening represents a great opportunity to potentially engage pharmacists with patients who may be less likely to access physicians including elderly patients, and patients from lower socio-economic status [3]. The majority of research in hepatitis C disease focused on the detection , diagnosis and treatment. However, in this research we focused on the metabatic and hypertension risk associated with hepatitis C infection in Egyptian population. Virus C is considered as a gigantic endemic therapeutic health issue in Egypt [4] . Egypt was found to have the most elevated recorded predominance of HCV in the world [5] [6]. Incidence rate is between 2 and 6 per 1000 case per year and 170,000 new cases are added each year [4] . Although mortality related to HCV infection will continue to extend over the following 20 years but, with successful therapeutic strategies it may be eliminated within 15-20 years [6]. Therefore , Egypt has propelled an ambitious new national treatment program in 2014 [7] . The Egyptian national HCV treatment program is considered one of the foremost fruitful, compelling and promising public health programs [8] .Chronic hepatitis C is the most cause of cirrhosis and hepatocellular carcinoma. Hepatitis C is characterized by being a slowly progressing liver illness, which implies that cirrhosis may happen almost 20–30 years after infection [9] . The primary host cells for HCV are hepatocytes. Viral entry into hepatocytes occurs following to its binding to low-density lipoprotein receptors. Once internalized, HCV interferes with the host lipid metabolism for its replication and assembly, which consequently leads to hepatic steatosis. Hepatic steatosis could be a condition in which there is excessive accumulation of triglycerides inside the hepatocytes. Strong epidemiological, biochemical, and therapeutic evidence implicate insulin resistance as the essential pathophysiological key mechanism driving to hepatic steatosis. A mixture of several host and viral factors cause hepatic steatosis[10] . First, host factors incorporate the metabolic syndromes such as obesity and type 2 diabetes mellitus (T2DM), hypertension, alcohol abuse and medication use. Second, hereditary factors as interleukin 28B polymorphism. Third facor is viral components as genotype (genotype 3 prima rily cause steatosis), and gene mutation [10] . It is very useful to distinguish modifiable risk factors that contribute to HCV progression it may guide treatment approaches and overall disease management. Impact of obesity and DM have been entangled within the progression of hepatic fibrosis and cirrhosis [8]. Recently, many studies have suggested that chronic hepatitis C virus infection (CHC) is associated with T2DM, However the association between CHC and T2DM is not consistent across all studies [11] . Another study in France detailed that HCV frequency was significantly related with age [12] . Previous studies demonstrated that HCV infection might not only resist antiviral course of treatment but also moreover advancement of fibrosis may happen which is due to expanded proficiency of viral replication by lipid accumulation in cells [11] . Lessening in complications from T2DM that follows effective antiviral treatment was detailed in later clinical trials [13] . The current study points to target high risk HCV Egyptian patients with metabolic disorders including diabetes, obesity , hypertension , age and sex then estimate the potential risk factors associated with hepatitis C patients and determine the impact of different screening methods for identifying and treating people at high risk